医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Heartseed Named “Healthcare Company of the Year 2020” by Healthcare Insights Magazine in the MedTech Category for Making a Crucial Impact in Healthcare

2020年12月01日 AM10:33
このエントリーをはてなブックマークに追加


 

TOKYO

Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (hereinafter HF), today announced that they have been named 2020 Healthcare Company of the Year in the MedTech category by Healthcare Insights, a leading magazine in the healthcare industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130006013/en/

Healthcare Company of the Year 2020 (Graphic: Business Wire)

Healthcare Company of the Year 2020 (Graphic: Business Wire)

This decision came after a review of healthcare companies from Asia Pacific in various segments by Healthcare Insights’ panel of judges who unanimously agreed to give Heartseed this title. This recognition acknowledges healthcare companies that are making a crucial impact in healthcare. It salutes dedicated companies that have worked hard to gain trust from customers and partners.

“Since our establishment in November 2015, we have been preparing hard to initiate clinical trials with the strong support of our stakeholders. The year 2021 will be a big step for us to achieve the First-in-Human trial.” said Keiichi Fukuda, Heartseed’s CEO. “We are honored to be named 2020 Healthcare Company of the Year in the Med Tech category on the day of our 5th anniversary. I believe this nomination is a reflection of their expectation of the therapeutic potential of our first-in-class iPS cell-derived cardiomyocytes transplantation that achieves remuscularization of the failing heart”.

After announcing USD 26 million Series B financing a year ago, Heartseed has accelerated their IND-enabling activities with a strong and diversified leadership team. Heartseed expects to initiate Phase 1/2 clinical trial (LAPiS Study) for its lead pipeline HS-001 for HF in 2021. Heartseed is also supporting an investigator-initiated clinical trial for HF (IPSCS Study) at Keio University, Japan.

https://jrct.niph.go.jp/en-latest-detail/jRCTa032200189

The magazine, Healthcare Insights, reaches out to over 74,000 subscribers across the APAC. Their mission is to help readers identify the companies that are bringing reliable and innovative solutions to the healthcare sector.

The December issue features the “Healthcare Companies of the year 2020” that have pushed the envelope of the health care industry with their inspiring ideas and advanced health care solutions.

Visit https://thehealthcareinsights.com/heartseed-revolutionizing-the-regenerative-medicine-industry-with-unique-portfolio-of-products/ to view the article.

For more information on Heartseed, please visit http://www.heartseed.jp/en/index.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20201130006013/en/

CONTACT

Kikuo Yasui, COO, Heartseed Inc.

Tel: +81-3-6380-1068

Email: kikuo.yasui@heartseed.jp

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • SETi’s Violeds Technology Solution to Support Delta Variant Spreading Prevention
  • Seoul Viosys Reports Record-High Second Quarter 2021 Results
  • Tiens Group Held an International Health Industry Forum
  • Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
  • Engrail Therapeutics 宣布扩展A轮融资至6400万美元